Last €112.28 EUR
Change Today +0.58 / 0.52%
Volume 250.0
XP2 On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 11:38 AM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

salix pharmaceuticals ltd (XP2) Snapshot

Open
€111.29
Previous Close
€111.69
Day High
€112.67
Day Low
€111.03
52 Week High
09/23/14 - €137.48
52 Week Low
11/7/14 - €65.74
Market Cap
7.2B
Average Volume 10 Days
45.8
EPS TTM
--
Shares Outstanding
63.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SALIX PHARMACEUTICALS LTD (XP2)

salix pharmaceuticals ltd (XP2) Related Businessweek News

No Related Businessweek News Found

salix pharmaceuticals ltd (XP2) Details

Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States. The company provides XIFAXAN tablets to treat overt hepatic encephalopathy, and patients with travelers’ diarrhea; APRISO too maintain remission of ulcerative colitis (UC); MOVIPREP and OSMOPREP for cleansing of the colon as a preparation for colonoscopy in adults; RELISTOR for the treatment of opioid-induced constipation (OIC) in patients with advanced illness; SOLESTA to treat fecal incontinence; and DEFLUX to treat vesicoureteral reflux. It also offers FULYZAQ for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy; GIAZO, COLAZAL, and UCERIS to treat mildly to moderately active UC; and METOZOLV ODT for the treatment of refractory gastroesophageal reflux disease (GERD) that fails to respond to conventional therapy. Its products also comprise AZASAN azathioprine tablets, which are used as adjunct to prevent rejection in renal homotransplantations and to reduce signs and symptoms of severe active rheumatoid arthritis; ANUSOL-HC and PROCTOCORT for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and PEPCID for the short-term treatment of GERD, active duodenal ulcer, active benign gastric ulcer, erosive esophagitis due to GERD, and peptic ulcer diseases. In addition, the company provides DIURIL to treat hypertension and also as adjunctive therapy; ZEGERID for the treatment of upper gastrointestinal conditions; GLUMETZA and CYCLOSET to enhance glycemic control in adults with type 2 diabetes mellitus; and FENOGLIDE to treat lipoprotein-cholesterol, total cholesterol, triglycerides, and apolipoprotein B, as well as hypertriglyceridemia. It has strategic collaboration with RedHill Biopharma Ltd. Salix Pharmaceuticals, Ltd. was founded in 1989 and is headquartered in Raleigh, North Carolina.

555 Employees
Last Reported Date: 02/28/14
Founded in 1989

salix pharmaceuticals ltd (XP2) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $867.5K
Chief Development Officer, Chief Medical Offi...
Total Annual Compensation: $466.4K
Executive Vice President of Business Developm...
Total Annual Compensation: $437.0K
Compensation as of Fiscal Year 2013.

salix pharmaceuticals ltd (XP2) Key Developments

Salix Pharmaceuticals, Ltd. Announces Management Changes

Salix Pharmaceuticals Ltd. announced that Carolyn Logan has informed the board of her decision to retire as president and chief executive officer, and as a director, of the company, effective January 30, 2015. Ms. Logan will remain a consultant to the company. Effective January 30, 2015, Mr. D Alonzo, who has significant experience as a chief executive in the pharmaceutical industry, will be appointed acting chief executive officer, and William Bertrand, Jr., the company’s senior vice president and general counsel, will be appointed acting chief operating officer, pending the company’s hiring of a permanent chief executive officer.

The Law Offices of Vincent Wong Notify Investors of Class Action Involving Salix Pharmaceuticals, Ltd. and a Lead Plaintiff Deadline of January 6, 2015

The Law Offices of Vincent Wong announced that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Salix Pharmaceuticals Ltd. securities between November 8, 2013 and November 6, 2014. The complaint alleges that the company made false and misleading statements and/or concealed material information regarding deteriorating demand and increasing inventory levels for Xifaxan and other Salix drugs.

Paulson Reportedly Takes Stake In Salix

Paulson & Co. Inc. has taken a stake in Salix Pharmaceuticals Ltd. (NasdaqGS:SLXP), according to people familiar with the matter. The size of Paulson's stake was not immediately clear, the people said. Paulson declined to comment. A spokesman for Salix declined to comment.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XP2:GR €112.28 EUR +0.58

XP2 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $71.39 USD +1.58
Jazz Pharmaceuticals PLC $175.74 USD +0.185
Lupin Ltd 1,489 INR -14.00
Recordati SpA €14.14 EUR +0.05
View Industry Companies
 

Industry Analysis

XP2

Industry Average

Valuation XP2 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.8x
Price/Book 15.2x
Price/Cash Flow 80.9x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SALIX PHARMACEUTICALS LTD, please visit www.salix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.